Oncopeptides Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
69
- Stock Symbol
-
ONCO
- Share Price
-
$0.16
- (As of Friday Closing)
Oncopeptides General Information
Description
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
Contact Information
Website
www.oncopeptides.comCorporate Office
- Luntmakargatan 46, 7 tr
- 111 37 Stockholm
- Sweden
Corporate Office
- Luntmakargatan 46, 7 tr
- 111 37 Stockholm
- Sweden
Oncopeptides Stock Performance
As of 20-Nov-2026, Oncopeptides’s stock price is $0.16. Its current market cap is $69.4M with 431M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.16 | $0.17 | $0.14 - $0.58 | $69.4M | 431M | 5.34M | -$0.07 |
Oncopeptides Financials Summary
As of 30-Sep-2026, Oncopeptides has a trailing 12-month revenue of $11M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 81,152 | 132,889 | 17,796 | 56,750 |
| Revenue | 11,015 | 7,239 | 2,992 | 3,314 |
| EBITDA | (19,603) | (23,003) | (25,530) | (22,600) |
| Net Income | (20,863) | (25,404) | (26,911) | (23,437) |
| Total Assets | 17,594 | 14,714 | 22,132 | 23,852 |
| Total Debt | 14,047 | 15,148 | 12,844 | 13,137 |
Oncopeptides Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Oncopeptides Comparisons
Industry
Financing
Details
Oncopeptides Competitors (14)
One of Oncopeptides’s 14 competitors is Swedish Orphan Biovitrum, a Formerly VC-backed company based in Stockholm, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum | Formerly VC-backed | Stockholm, Sweden | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Karyopharm Therapeutics | Formerly VC-backed | Newton, MA | ||||
| CSL Behring (Biotechnology) | Corporation | Vienna, Austria | ||||
| Cellectis | Formerly VC-backed | Paris, France |
Oncopeptides Patents
Oncopeptides Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202413825-D0 | Novel therapeutic treatments | Inactive | 19-Sep-2024 | ||
| WO-2026057823-A1 | Bis-chloroethylamino derivatives for treating leukemia | Pending | 13-Sep-2024 | ||
| GB-202410121-D0 | Novel polypeptides | Inactive | 11-Jul-2024 | ||
| GB-202318674-D0 | Novel polypeptides | Inactive | 06-Dec-2023 | ||
| GB-202318675-D0 | Novel polypeptides | Inactive | 06-Dec-2023 | C07K14/70535 |
Oncopeptides Signals
Oncopeptides Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Oncopeptides ESG
Risk Overview
Risk Rating
Updated September, 30, 2025
29.34 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
Oncopeptides FAQs
-
When was Oncopeptides founded?
Oncopeptides was founded in 2000.
-
Where is Oncopeptides headquartered?
Oncopeptides is headquartered in Stockholm, Sweden.
-
What is the size of Oncopeptides?
Oncopeptides has 69 total employees.
-
What industry is Oncopeptides in?
Oncopeptides’s primary industry is Biotechnology.
-
Is Oncopeptides a private or public company?
Oncopeptides is a Public company.
-
What is Oncopeptides’s stock symbol?
The ticker symbol for Oncopeptides is ONCO.
-
What is the current stock price of Oncopeptides?
As of 20-Nov-2026 the stock price of Oncopeptides is $0.16.
-
What is the current market cap of Oncopeptides?
The current market capitalization of Oncopeptides is $69.4M.
-
What is Oncopeptides’s current revenue?
The trailing twelve month revenue for Oncopeptides is $11M.
-
Who are Oncopeptides’s competitors?
Swedish Orphan Biovitrum, AbbVie, Karyopharm Therapeutics, CSL Behring (Biotechnology), and Cellectis are some of the 14 competitors of Oncopeptides.
-
What is Oncopeptides’s annual earnings per share (EPS)?
Oncopeptides’s EPS for 12 months was -$0.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process